TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9373242

Group type: EXPERIMENTAL
Intervention: Autologous CD34(+) marrow graft (Arm A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard buffy coat fraction (Arm B)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Autologous CD34(+) marrow graft (Arm A) with >/=1.2 x 10(6) CD34(+) cells/kg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard buffy coat fraction (Arm B) with >1.2 x 10(6) CD34(+) cells/kg
Number of subjects: 89
Study: 1392429

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 37
Study: 3965335

Group type: EXPERIMENTAL
Intervention: 8.5‐mm endoscope with diazepam
Number of subjects: 146

Group type: COMPARATOR
Intervention: 8.5‐mm endoscope with no sedation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 11.5‐mm endoscope with diazepam
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Diazepam sedation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Smaller endoscope (8.5‐mm)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Patients with prior history of cardiovascular disease
Number of subjects: 146
Study: 31210421

Group type: EXPERIMENTAL
Intervention: RDP using the “3+2” mode
Number of subjects: 106

Group type: COMPARATOR
Intervention: RDP using the classical mode
Number of subjects: 106
Study: 29530088

Group type: EXPERIMENTAL
Intervention: Praziquantel (60 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 27341346

Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention
Number of subjects: 632

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 632
Study: 24804281

Group type: EXPERIMENTAL
Intervention: Autogenous hard and soft tissue grafts
Number of subjects: 49
Study: 22285755

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intensive exercise
Number of subjects: 106

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 106
Study: 20348359

Group type: EXPERIMENTAL
Intervention: Catholic‐tailored program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard behavioral program
Number of subjects: 34
Study: 18550081

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) at weeks 0, 2, 6, and 14 with MTX (10‐17.5 mg/week) and prednisolone (<10 mg/day)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 5
Study: 11581553

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) at a dose of 3.5 mg/kg body weight administered by deep intramuscular injection once a week for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline-based placebo (nonTE)
Number of subjects: 10
Study: 9692843

Group type: EXPERIMENTAL
Intervention: VIPE regimen
Number of subjects: 27

Group type: COMPARATOR
Intervention: EC regimen
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: DexaBEAM regimen
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CHOEP regimen
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EPI/IFOS regimen
Number of subjects: 27
Study: 8025393

Group type: EXPERIMENTAL
Intervention: Individualized dietary counselling with a fat content of 35-45 E% of total energy intake (7-12 months) and 30-35 E% after 12 months, with a fatty acid ratio of 1:1:1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group with no specific dietary advice
Number of subjects: 45
Study: 2901743

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Misoprostol and Cimetidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gastric juice somatostatin concentration
Number of subjects: 45
Study: 31786177

Group type: EXPERIMENTAL
Intervention: Tailored nutrition counseling once per month for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group received the same educational resource at baseline without any discussion
Number of subjects: 120
Study: 30396708

Group type: EXPERIMENTAL
Intervention: iTero
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lava
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cerec infiniDent
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional workflow
Number of subjects: 10
Study: 28808847

Group type: EXPERIMENTAL
Intervention: Hyoscine N-butyl bromide (20 mg, slow intravenous injection)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study: 26259134

Group type: EXPERIMENTAL
Intervention: GH 1 mg/m(2) per day with GnRHa
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2) per day with GnRHa
Number of subjects: 107

Group type: COMPARATOR
Intervention: GH 1 mg/m(2) per day
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: GH 2 mg/m(2) per day
Number of subjects: 107
Study: 23411653

Group type: EXPERIMENTAL
Intervention: Spiritual and religious beliefs and practices
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Income
Number of subjects: 132
Study: 22071701

Group type: EXPERIMENTAL
Intervention: Iron supplementation (2 mg/kg daily)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Iron supplementation (1 mg/kg daily)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo (0 mg/kg daily)
Number of subjects: 285
Study: 19164454

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine ± platinum-based chemotherapy
Number of subjects: 1775
Study: 16298507

Group type: EXPERIMENTAL
Intervention: Lafutidine
Number of subjects: 0
Study: 15550855

Group type: EXPERIMENTAL
Intervention: Docetaxel plus capecitabine
Number of subjects: 511

Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 511
Study: 10680804

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: PMH/SMS involving at least two areas combined with absence of early CT signs
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: PMH/SMS involving three areas
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Absence of early CT signs
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Leukoaraiosis or previous lacunar infarcts
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: PMH/SMS plus leukoaraiosis or previous lacunes
Number of subjects: 514
Study: 9424969

Group type: EXPERIMENTAL
Intervention: 26-gauge Quincke cannula
Number of subjects: 481

Group type: COMPARATOR
Intervention: 27-gauge Quincke cannula
Number of subjects: 481

Group type: COMPARATOR
Intervention: 26-gauge Atraucan cannula
Number of subjects: 481

Group type: COMPARATOR
Intervention: 27-gauge Whitacre cannula
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Recumbency (bed rest for 24 hours)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Early ambulation (getting up as early as possible)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 481
Study: 8382919

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (2500 IU)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Nadroparin calcium (3075 IU)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 194
Study: 30699415

Group type: EXPERIMENTAL
Intervention: Enarodustat 2 mg, 4 mg, or 6 mg once daily for 6 weeks (Period 1) followed by 24 weeks of open enarodustat treatment (Period 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enarodustat (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enarodustat
Number of subjects: 0
Study: 28185996

Group type: EXPERIMENTAL
Intervention: Shade sails in passive recreation areas (PRAs)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Unshaded PRAs
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Shade sails in PRAs
Number of subjects: 145
Study: 26805494

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity, nutritional education, telephone call counseling, health counseling, monitoring for lifestyle, affective support) for six weeks
Number of subjects: 49
Study: 24093847

Group type: EXPERIMENTAL
Intervention: Myocardial blush grade 2/3
Number of subjects: 2367

Group type: EXPERIMENTAL
Intervention: ST-segment resolution ≥50%
Number of subjects: 2367

Group type: COMPARATOR
Intervention: Myocardial blush grade 0/1
Number of subjects: 2367
Study: 21394123

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glass Ionomer Cement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resin Composite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative Control Group
Number of subjects: 0
Study: 18491405

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Long-term statin use
Number of subjects: 19
Study: 16829768

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy after 16 hours (group A)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Lymphoscintigraphy after 2.5 hours (group B)
Number of subjects: 682
Study: 15452046

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide
Number of subjects: 33
Study: 11302591

Group type: EXPERIMENTAL
Intervention: Universal testing machine (in vitro)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Debonding device (in vitro)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Debonding device (in vivo)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (in vitro)
Number of subjects: 8
Study: 9069477

Group type: EXPERIMENTAL
Intervention: Multiple system atrophy with vocal cord palsy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple system atrophy without vocal cord palsy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both MSA groups
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MSA with vocal cord palsy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MSA without vocal cord palsy
Number of subjects: 12
Study: 8441107

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (dextrose in water)
Number of subjects: 29
Study: 3535158

Group type: EXPERIMENTAL
Intervention: Aspirin (high-dose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aspirin (low-dose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heparin-Dihydroergotamine (heparin-DHE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 30032466

Group type: EXPERIMENTAL
Intervention: Transforaminal anterolateral (TFA) approach
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Transforaminal posterolateral (TFP) approach
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Transfacet indirect (TFT) approach
Number of subjects: 104
Study: 26932797

Group type: EXPERIMENTAL
Intervention: H. pylori eradication regimen (pantoprazole 40 mg b.i.d., bismuth subcitrate 120 mg q.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d. for 14 days)
Number of subjects: 80
Study: 24808113

Group type: EXPERIMENTAL
Intervention: Printed list only
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Open‐ended question only
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Combined intervention (printed list + open‐ended question)
Number of subjects: 440

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 440
Study: 22313644

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no CHX gel)
Number of subjects: 100
Study: 19581281

Group type: EXPERIMENTAL
Intervention: Intensive treatment strategy with methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment strategy with methotrexate (MTX)
Number of subjects: 0
Study: 18794104

Group type: EXPERIMENTAL
Intervention: Intravenous IL-2 (18 x 10(6) IU/m(2)/d) + s.c. IFN-alpha (6 x 10(6) IU 3 days/week)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Subcutaneous IL-2 (9 x 10(6) or 18 x 10(6) IU) + s.c. IFN-alpha (6 x 10(6) IU 3 days/week)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Intravenous IL-2
Number of subjects: 155

Group type: COMPARATOR
Intervention: Subcutaneous IL-2
Number of subjects: 155
Study: 15945310

Group type: EXPERIMENTAL
Intervention: Resin-bonded fixed partial dentures (FPDs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional three-unit FPDs (metal-ceramic crowns or complete cast-metal crowns)
Number of subjects: 20
Study: 15071264

Group type: EXPERIMENTAL
Intervention: DDD-R pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restoration of chronotropic competence by pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: VVI-R pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 0
Study: 10475719

Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg orally) after TYR-free amino acid mixture
Number of subjects: 15

Group type: COMPARATOR
Intervention: d-amphetamine (20 mg orally) after nutritionally balanced amino acid mixture
Number of subjects: 15
Study: 8911291

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 1990902

Group type: EXPERIMENTAL
Intervention: N2O/morphine anesthesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: halothane 0.8%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: enflurane 1.7%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: isoflurane 1.4%
Number of subjects: 32
Study: 6355051

Group type: COMPARATOR
Intervention: Intravenous acyclovir
Number of subjects: 0
Study: 31764675

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30206194

Group type: EXPERIMENTAL
Intervention: Group REBT program (8 sessions, 180 minutes each, once a week)
Number of subjects: 47
Study: 26704170

Group type: EXPERIMENTAL
Intervention: Standard therapy (ACTH, oral corticosteroids, vigabatrin)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Nonstandard therapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Other nonstandard therapies
Number of subjects: 230
Study: 25182696

Group type: EXPERIMENTAL
Intervention: Switching to a biologic drug based on NICE guidelines
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Physician's choice for switching biologic drugs
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Discontinuation of a biologic drug due to lack of effect
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Use of Methotrexate in switches to Rituximab
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Overall compliance with NICE guidance
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Switching from anti-TNFα to anti-TNFα for inefficacy
Number of subjects: 317
Study: 22322086

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 6198

Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 6198

Group type: COMPARATOR
Intervention: Stress test results
Number of subjects: 6198
Study: 20884411

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 220
Study: 17825729

Group type: EXPERIMENTAL
Intervention: COPE Healthy Lifestyles TEEN program (15-session cognitive-behavioral skills building program including physical activity)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Attention control program (for the control group)
Number of subjects: 23
Study: 15610695

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel agents targeting vascular endothelial growth factor
Number of subjects: 0
Study: 12585186

Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI)
Number of subjects: 35
Study: 10897293

Group type: EXPERIMENTAL
Intervention: Cut versions of films
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncut versions of films
Number of subjects: 0
Study: 7587188

Group type: EXPERIMENTAL
Intervention: Lea's Shield with spermicide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lea's Shield with non-spermicidal lubricant
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Contraceptive diaphragm with spermicide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline cycle (no contraceptive barrier)
Number of subjects: 10
Study: 1783248

Group type: EXPERIMENTAL
Intervention: Lactitol (20 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Maltitol (20 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isomalt (20 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sorbitol (20 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Lactulose (10 g)
Number of subjects: 6
Study: 7073996

Group type: EXPERIMENTAL
Intervention: Telemetric monitoring with mobility option
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Telemetric monitoring (staying in bed)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Telemetric monitoring
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ambulant patients with spontaneous deliveries
Number of subjects: 200
Study: 30628875

Group type: EXPERIMENTAL
Intervention: Mentalization-Based Lighthouse Parenting Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27858112

Group type: EXPERIMENTAL
Intervention: Sabbagh Universal Spring 2 (SUS 2) fixed functional appliance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Maxillary premolar extraction
Number of subjects: 40
Study: 25028999

Group type: EXPERIMENTAL
Intervention: High weight reduction group (HWR; energy restriction 750 kcal·d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low weight reduction group (LWR; energy restriction 300 kcal·d)
Number of subjects: 15
Study: 23617466

Group type: EXPERIMENTAL
Intervention: Concept maps (CMs) used in problem-based learning (PBL) tutorials
Number of subjects: 172

Group type: COMPARATOR
Intervention: Non-concept maps (non-CM) used in problem-based learning (PBL) tutorials
Number of subjects: 172
Study: 22072362

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Parenteral Nutrition (TPN)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both EN and TPN
Number of subjects: 22
Study: 20467617

Group type: EXPERIMENTAL
Intervention: Emdogain
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17562928

Group type: EXPERIMENTAL
Intervention: Idebenone at a maximum dose of 75 mg/kg in phase 1A
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Idebenone at 60 mg/kg per day for 1 month in phase 1B
Number of subjects: 93
Study: 15155308

Group type: EXPERIMENTAL
Intervention: IV KET (9 microg. kg(‐1). min(‐1); 45 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: IV KET (9 microg. kg(‐1). min(‐1); 45 min) plus MO (10 microg. kg(‐1). min(‐1); 10 min)
Number of subjects: 11

Group type: COMPARATOR
Intervention: MO (10 microg. kg(‐1). min(‐1); 10 min)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (saline; 10 min)
Number of subjects: 11
Study: 11202757

Group type: EXPERIMENTAL
Intervention: VSQLQ administered via personal interview
Number of subjects: 304
Study: 9222910

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel decompression
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Open carpal tunnel decompression
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal individuals (control group)
Number of subjects: 100
Study: 1542838

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with morphine sulfate
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intramuscular (IM) morphine sulfate
Number of subjects: 55
Study: 3933984

Group type: EXPERIMENTAL
Intervention: Glibenclamide (10 mg, once daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glipizide (10 mg, once daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31097971

Group type: EXPERIMENTAL
Intervention: Tian Jiu (TJ) therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 138
Study: 30571753

Group type: EXPERIMENTAL
Intervention: Strength training group (n = 76)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Balance training group (n = 75)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Comparison between strength and balance groups
Number of subjects: 151
Study: 26708025

Group type: EXPERIMENTAL
Intervention: Simulation education session
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 25240556

Group type: EXPERIMENTAL
Intervention: Wool cap (90 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No wool cap (90 min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Wool cap
Number of subjects: 18

Group type: COMPARATOR
Intervention: No wool cap
Number of subjects: 18
Study: 22692351

Group type: EXPERIMENTAL
Intervention: Involved-field (IF) radiotherapy, total of 30 Gy
Number of subjects: 3710
Study: 20819551

Group type: EXPERIMENTAL
Intervention: Two-site phacotrabeculectomy
Number of subjects: 2
Study: 18670229

Group type: EXPERIMENTAL
Intervention: Prospective HLA-B*5701 screening
Number of subjects: 0
Study: 17140502

Group type: EXPERIMENTAL
Intervention: ALPHA form
Number of subjects: 227

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 227
Study: 15600133

Group type: EXPERIMENTAL
Intervention: Problems writing group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hobbies writing group
Number of subjects: 42

Group type: COMPARATOR
Intervention: No writing group
Number of subjects: 42
Study: 10663912

Group type: EXPERIMENTAL
Intervention: Rotablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 0